This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
STOCK PICK OF 2021?
built for growth,
driving value
One of the leading Canadian B2B post-harvest solutions providers, Ayurcann is one of the most innovative publicly traded companies in the adult and medical-use markets.
CSE:AYUR is focused on becoming the partner of choice for leading Canadian brands and yielding continuous returns for investors.
Is this your opportunity to join the $10.1 billion 2.0 market?
+67%
increase in net revenue
$2.6 Million Q3 2021 vs $1.56 Million Q2
+509%
increase in gross margin
$1.84 Million Q3 2021 v/s $302,200 Q2
$1.08 Mil
Adjusted EBIDTA in Q3
representing gross margins of approximately 70%
Get the latest investor news
MARKET OPPORTUNITY
A Rapidly Growing 2.0 Market Segment
As the 2.0 market matures, it moves away from vertical integration.
The 2.0 market is growing at an exponential rate – what's an emerging market of today will transition into a mature industry lead by companies that specialize and develop competitive advantages in the value chain.
Ayurcann is well-positioned to capitalize on the 2.0 market evolution
Canadian 2.0 Market*
Canadian 2.0 Segment Sales Growth**
*Source: Stats Canada and equity research
**Source: MF & C Manufacturers Guild
the value chain
Ayurcann's Competitive Advantage
- Leading 2.0 Product Manufacturer
- Very low OPEX = Massive Operating Leverage
- High Gross Margins
- High-Margin Branded Product Offerings
- EBITDA and Cash Flow Positive
- Debt Free
Ayurcann is a leading extraction company in Canada, focused on providing and creating custom processes and pharma-grade products for the adult and medical use markets.
COMPETITIVE
- Extraction and Refinement
- Bulk Oil Sales
- White Label Manufacturing
CERTIFIED
- Health Canada Standard Processing Licensed
- Health Canada R&D Licensed
- Amended License for Sales to Provincial Distributors and Retailers
INNOVATIVE
- In-house R&D
- Flexible Production
- Experienced Expert Team
- Turnkey Solutions Availability
Get the latest investor news
Top Services + TOP PRODUCTS + Competitive Yet PROFITABLE PRICING =
Key Success Factors
Services to Partners & Brands
Efficient technology + infrastructure providing top quality, timely service at competitive pricing
Proven traction with over 20 clients and counting
Medicinal
Line of Products
XPLOR brand serves medicinal B2B market, 6 SKUs at launch
Ayurcann Marketplace now offering direct sales to registered patients
Operational & Financial Excellence
Over $4.1 million in revenue booked between 2020 Q1-Q3 alone
Over $1 million in adjusted EBITDA
Low OPEX relative to competitors
Offerings
Competitive Product Lines
Extraction & Refinement
- Processed over 16,000 kgs of biomass, to date
- Ethanol extraction specialty
- Low to high volume production capabilities
- Fast and flexible production
Bulk Oil Sales
- Secured monthly biomass supply
- Over 300 kg monthly distillate inventory
- Inventory-to-supply leading license producers, supporting edibles, topicals, and inhalables
- Quality supply of crude, distillate, and isolates
White Label Manufacturing
- In-house developed IP formulation
- 20+ product offering SKUs
- Custom extracts and formulations
- Branding and packaging capabilities
COMPETITIVE VALUE
Attractive Valuation Relative to Peer Group
Now is the Time to Join Us
Before the Rest of the Market Catches On
This hidden gem won't stay in the shadows for long.
With strong revenue forecasts extending into 2022, Ayurcann is built for long-term growth, driving value for CSE:AYUR shareholders.
The Canadian 2.0 market is leading worldwide industry growth, and Ayurcann is positioned to gain fair market share.
Is this the early investor opportunity that you have been waiting for?
Find out now. Get the Investor Presentation.
© Ayurcann Inc. 2021 © Proactive 2021 All Rights Reserved
Contact Investor Relations:
NO INVESTMENT ADVICE
This website is published on behalf of Ayurcann Holdings Inc., who is a paid client of Proactive Investors. Proactive Investors received either monetary or securities compensation for our services. This site provides general information and discussions about health and financial subjects. The information in this site, or any linked materials, is not intended to replace medical or financial advice, nor is the information a substitute for professional expertise, treatment, or financial recommendations. If you or any person has a medical or financial concern, you should consult with your health care provider or financial advisor.